Takeda and Protagonist Therapeutics’ rusfertide, to be branded as Mimrylo, received FDA approval for polycythemia vera, a rare myeloproliferative blood disorder. The regulatory nod makes the first prescription path for Mimrylo in the U.S. for patients with polycythemia vera, according to the companies’ announcement. Rusfertide is positioned as a new treatment option for a population with high unmet need, where disease control and durable symptom management remain central. The approval also adds to Takeda’s hematology portfolio as it continues expanding into rare-disease pathways. For clinicians and payers, the key near-term question will be how Mimrylo’s label integrates with existing standard-of-care approaches and how it performs under real-world prescribing patterns.